Melqart Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Melqart Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-134,000	Closed	-$16.9M	–	29
2018 Q3	$16.9M	Sell	134,000 -256,600	-66%	-$27.2M	1.58%	19
2018 Q2	$32.8M	Buy	390,600 +92,400	+31%	+$6.77M	2.8%	12
2018 Q1	$18.3M	Buy	298,200 +73,200	+33%	+$4.41M	2.21%	16
2017 Q4	$13.1M	Buy	+225,000	New	+$14.2M	2.13%	13

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Melqart Asset Management's ICPT Position: Q4 2018 in Review

Melqart Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2018, closing a stake of 134,000 shares — an estimated $16.9M sold.

Melqart Asset Management first reported a position in ICPT in Q4 2017 and held it in 4 quarters. The position peaked at $32.8M in Q2 2018. 191 funds tracked by Wall St. Rank hold ICPT as of Q4 2018.

Melqart Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Melqart Asset Management sold 134,000 Intercept Pharmaceuticals, Inc. shares in Q4 2018, an estimated $16.9M.
Melqart Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2017 and held it in 4 quarters.
Melqart Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $32.8M in Q2 2018.
191 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2018.

Based on Melqart Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.